Wolfe Research Initiates Coverage of UniQure (QURE) With a Peer Perform Rating

UniQure (NASDAQ:QURE) is one of the top gene therapy stocks to buy according to hedge funds. Wolfe Research initiated coverage of UniQure (NASDAQ:QURE) with a Peer Perform rating on February 23, without assigning a price target. The firm stated that it launched coverage of the neuroscience biotech sector with a “portfolio of high conviction names across multiple therapeutic areas”, adding that it requires additional clarity on UniQure’s (NASDAQ:QURE) lead program AMT-130 before recommending the shares.

UniQure (NASDAQ:QURE) also received a rating update from H.C. Wainwright on February 10, with the firm reiterating a Buy rating on the stock and setting a $70.00 price target. It supported the optimistic rating with several factors, including the strengthening of uniQure’s gene therapy platform as demonstrated by new Fabry disease data.

The firm also considers the emerging safety profile and clearer dose window as constructive, with the observed liver enzyme elevations being manageable and helping refine future dosing instead of derailing development. According to H.C. Wainwright, the Fabry data, along with the ongoing progress in the CNS pipeline and a solid balance sheet, are not yet near-term regulatory catalysts. However, they do add meaningful, longer-term value that is not fully reflected in the current share price.

UniQure (NASDAQ:QURE) discovers, develops, and commercializes innovative gene therapies, with its discoveries focused on treating Huntington’s disease, glybera, hemophilia, and cardiovascular problems.

While we acknowledge the potential of QURE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.